Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Lesalpes29on Jan 25, 2023 9:18am
194 Views
Post# 35244738

RE:Interest of BP for a buyout.

RE:Interest of BP for a buyout.
Lesalpes29 wrote: How can we evaluate the probability of it!
Parsons and Rigby are in for a buyout I think.
When you have said that... you have to look at all results from multiple studies that are already known or unknown. Negociations are already on I think again! Why on heart you would bring two new members on the BOD if they do nothing for ower cause! That doesn't make sense. Of course you have to believe that the rest of the board want to cash their options! I think so! GL
And the other thing to ask is why two new board members? Why not only one? Multiple BP intetested maybe? Didn't follow Trillium Therapeutics close enough to see if we can compare ower story to it. Unfortunately!

<< Previous
Bullboard Posts
Next >>